Kindred Biosciences Launches Mirataz™ (mirtazapine transdermal ointment)
Kindred Biosciences, Inc., a biopharmaceutical company focused on saving and improving the lives of pets, announces the commercial launch of Mirataz™ (mirtazapine transdermal ointment) for the management of weight loss in cats.
Veterinarians can now immediately order Mirataz through their preferred animal health distributor, and pre-orders are shipping. In May 2018, Mirataz was approved by the U.S. Food & Drug Administration (FDA) Center for Veterinary Medicine (CVM), making it the first and only FDA-approved transdermal medication for the management of weight loss in cats.